NCT02401815: A trial that was reported late by Cogent Biosciences, Inc.
This trial has reported, although it was 530 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02401815 |
|---|---|
| Title | A Phase 1b and 2a Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CGT9486 as a Single Agent and in Combination With PLX3397 or Sunitinib (Sutent®) in Patients With Advanced Solid Tumors and Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated With Imatinib Mesylate/KIT-Directed Tyrosine Kinase Inhibitor (TKI) Therapy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 6, 2015 |
| Completion date | May 11, 2020 |
| Required reporting date | May 11, 2023, midnight |
| Actual reporting date | Oct. 22, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 530 |